

PRESS NEWS

Gradientech announces Notice of Allowance from Japanese Patent Office

Uppsala, March 16, 2018. Gradientech AB, a Swedish biotech and diagnostic company developing the next generation ultra-rapid antibiotic susceptibility testing (AST) system for appropriate treatment of sepsis, today announces that the Company has received a Notice of Allowance from the Japanese Patent Office (JPO) for patent application no. 2016-525331, “New Use of a Fluidic Device”. The patent application covers the proprietary minimum inhibitory concentration (MIC) determination of a bacteria sample within a microfluidic controlled environment that is part of the technology platform of the Company’s diagnostic system QuickMIC™ for ultra-rapid AST in development.

A Notice of Allowance signifies that Gradientech will be entitled to receive patent protection until 2034 in Japan for the allowed claims when the patent is issued. Gradientech has already been granted patent protection for MIC determination in Europe.

For further information, please contact:

Sara Thorslund, CEO

Tel: +46 736 29 35 80, email: sara.thorslund@gradientech.se

TO THE EDITORS

About Gradientech

Gradientech is a Swedish biotech and diagnostic company based on innovative microfluidic product development. We provide precision assays and software solutions for high-quality analysis of cell behavior in response to gradients of signalling molecules. Driven by the increased global prevalence of antibiotic resistance, Gradientech is developing its microfluidic platform QuickMIC™ - the most rapid IVD system for antibiotic susceptibility testing of sepsis patients.